使用生物制剂和JAK抑制剂对患者安全技能的评估：BioSecure问卷的更新 - Suppr | 超能文献

相似文献

1

Patients' safety skills assessment with biologics and JAK inhibitors: Update of the BioSecure questionnaire.使用生物制剂和JAK抑制剂对患者安全技能的评估：BioSecure问卷的更新

Joint Bone Spine. 2021 Oct;88(5):105215. doi: 10.1016/j.jbspin.2021.105215. Epub 2021 May 14.

2

[Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice with JAK inhibitors.].[类风湿关节炎的诊断与治疗：迈向最佳实践。JAK抑制剂的最佳应用。]

Clin Calcium. 2018;28(5):678-685.

3

[Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic disease-modifying antirheumatic drugs stand today?].[类风湿关节炎的药物治疗：生物制剂和新型合成改善病情抗风湿药目前处于什么地位？]

Inn Med (Heidelb). 2023 Oct;64(10):1005-1012. doi: 10.1007/s00108-023-01554-6. Epub 2023 Jul 26.

4

Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.类风湿关节炎患者中生物制剂和 JAK 抑制剂的心血管安全性。

Curr Rheumatol Rep. 2018 May 30;20(7):42. doi: 10.1007/s11926-018-0752-2.

5

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.EULAR 推荐的类风湿关节炎治疗策略：2019 年更新版（使用合成和生物疾病修正抗风湿药物）

Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22.

6

Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.最适合与类风湿关节炎不同先进疗法联合使用的常规疾病修饰抗风湿药物：系统文献回顾与荟萃分析。

Arthritis Care Res (Hoboken). 2021 Jun;73(6):873-884. doi: 10.1002/acr.24195.

7

JAK Inhibitors: What Is New?JAK 抑制剂：有何新进展？

Curr Rheumatol Rep. 2020 Jul 22;22(9):50. doi: 10.1007/s11926-020-00931-6.

8

Which should be first: biologic DMARDs or Janus kinase inhibitors?应该先用生物性改善病情抗风湿药还是 Janus 激酶抑制剂？

Rheumatology (Oxford). 2023 May 2;62(5):1738-1739. doi: 10.1093/rheumatology/keac629.

9

Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.类风湿关节炎患者体内的调节性T细胞频率可通过传统和生物性改善病情抗风湿药升高，但JAK抑制剂无此作用。

Ann Rheum Dis. 2021 Dec;80(12):e196. doi: 10.1136/annrheumdis-2019-216576. Epub 2019 Nov 19.

10

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?乙肝病毒与靶向合成（ts）改善病情抗风湿药：我们从生物改善病情抗风湿药和靶向合成改善病情抗风湿药中学到了什么？

RMD Open. 2020 Feb;6(1). doi: 10.1136/rmdopen-2020-001171.

引用本文的文献

1

Evaluation of the BIOSECURE Questionnaire in Patients Followed for Inflammatory Rheumatological and Gastrointestinal Diseases Through the Analysis of This Questionnaire.通过对生物安全问卷的分析评估该问卷在炎症性风湿性和胃肠道疾病患者中的应用情况。

J Clin Med. 2025 Jan 22;14(3):687. doi: 10.3390/jcm14030687.

2

Development and real-life use assessment of a self-management smartphone application for patients with inflammatory arthritis. A user-centred step-by-step approach.炎症性关节炎患者自我管理智能手机应用程序的开发及实际应用评估：以患者为中心的逐步方法。

PLoS One. 2022 Sep 15;17(9):e0272235. doi: 10.1371/journal.pone.0272235. eCollection 2022.

3